» Articles » PMID: 28754328

Age-related Levels of Fecal M2-pyruvate Kinase in Children with Cystic Fibrosis and Healthy Children 0 to 10years Old

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2017 Jul 30
PMID 28754328
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The pathogenesis of gut inflammation, bacterial dysbiosis and increased rates of malignancy in CF is unclear. Fecal M2-pyruvate kinase (M2-PK) is a biomarker indicative of cellular proliferation that may be raised in intestinal malignancy and inflammation. Biomarkers, including M2-PK, may be useful in assessing effects of novel therapies on the gastrointestinal tract.

Methods: M2-PK was measured in stools collected from patients with CF and HC (0-10years). Linear mixed model analysis was used.

Results: M2-PK levels did not significantly change in children with CF (36 patients, 77 samples) (P=0.998) or HC (45 patients, 45 samples) (P=0.21), over the age range 0-10years. Patients with CF had elevated M2-PK compared to HC (median [IQR; range]: 10.7 [5.7-28.6; 1.0-239.1] (n=77) vs. 1.0 [1.0-1.0; 1.0-50.0] (n=45) U/mL, respectively; P=0.001).

Conclusions: Fecal M2-PK was elevated in children with CF compared with HC during infancy and throughout childhood suggesting abnormalities in the CF gut exist in early life.

Citing Articles

Gastrointestinal Cancers in Hospitalized Patients with Cystic Fibrosis: A Nationwide Study, 2010-2020.

Wasuwanich P, Karnsakul W Diagnostics (Basel). 2024; 14(18).

PMID: 39335678 PMC: 11431327. DOI: 10.3390/diagnostics14181999.


Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Tam R, van Dorst J, McKay I, Coffey M, Ooi C J Clin Med. 2022; 11(3).

PMID: 35160099 PMC: 8836727. DOI: 10.3390/jcm11030649.


Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis.

Talebi S, Day A, Rezaiyan M, Ranjbar G, Zarei M, Safarian M Pediatr Gastroenterol Hepatol Nutr. 2022; 25(1):1-12.

PMID: 35087728 PMC: 8762598. DOI: 10.5223/pghn.2022.25.1.1.


Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis.

Hoskins B, Wasuwanich P, Scheimann A, Karnsakul W World J Gastrointest Oncol. 2021; 13(9):1121-1131.

PMID: 34616517 PMC: 8465437. DOI: 10.4251/wjgo.v13.i9.1121.


Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis.

Thavamani A, Salem I, Sferra T, Sankararaman S Metabolites. 2021; 11(2).

PMID: 33671639 PMC: 7926988. DOI: 10.3390/metabo11020123.